Publications

Publications 

Receiving four or fewer cycles of therapy predicts poor survival in newly diagnosed transplant-ineligible patients with myeloma who are treated with bortezomib-based induction.
Boyle S, Wellard C, Moore EM, Blacklock H, Harrison SJ, Ho PJ, Hocking J, McQuilten ZK, Quach H, Spearing R, Wood EM, Spencer A, Mollee P; Myeloma and Related Diseases Registry investigators. Eur J Haematol. 2021 Jun 15. Epub ahead of print.

Real-world utilisation of ASCT in multiple myeloma (MM): a report from the Australian and New Zealad myeloma and related diseases registry (MRDR).
Bergin K, Wellard C, Augustson B, Cooke R, Blacklock H, Harrison SJ, Ho J, King T, Quach H, Mollee P, Walker P, Moore E, McQuilten Z, Wood E, Spencer A; Australian and New Zealand Myeloma and Related Diseases Registry. Bone Marrow Transplant. 2021 May 19. Epub ahead of print.

The Myeloma Landscape in Australia and New Zealand (ANZ): The First Eight Years of the Myeloma and Related Diseases Registry (MRDR).
Bergin K, Wellard C, Moore EM, McQuilten Z, Augustson B, Blacklock H, Harrison SH, Ho PJ, King T, Quach H, Mollee P, Walker P, Wood EM, Spencer A, on behalf of the Australian and New Zealand Myeloma and Related Diseases Registry. Clin Lymphoma Myeloma Leuk. Published:January 29, 2021.

Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomized controlled trial. 
Moore EM, King TA, Wood EM, Ruseckaite R, Klarica D, Spencer A, Ho PJ, Quach H, Prince HM, McQuilten ZK. Am J Hematol. 2020 Jul;95(7):e178-181.

Renal Impairment at Diagnosis in Myeloma: Patient Characteristics, Treatment, and Impact on Outcomes. Results From the Australia and New Zealand Myeloma and Related Diseases Registry.
Ho PJ, Moore EM, McQuilten ZK, Wellard C, Bergin K, Augustson B, Blacklock H, Harrison SJ, Horvath N, King T, Mollee P, Quach H, Reid C, Rosengarten B, Walker P, Wood EM, Spencer A. Clin Lymphoma Myeloma Leuk. 2019 Aug;19(8):e415-e424.

Myeloma in the Real World: What Is Really Happening? 
Bergin K, McQuilten Z, Moore E, Wood E, Spencer A. Clin Lymphoma Myeloma Leuk. 2017 Mar;17(3):133-144.

Design and development of the Australian and New Zealand (ANZ) myeloma and related diseases registry. 
Bergin K, Moore E, McQuilten Z, Wood E, Augustson B, Blacklock H, Ho J, Horvath N, King T, McNeil J, Mollee P, Quach H, Reid CM, Rosengarten B, Walker P, Spencer A. BMC Med Res Methodol. 2016 Nov 9;16(1):151.

Presentations

2021

ISOQOL 28^th Annual Conference, Oct 2021 (virtual)

• E Moore: EQ-5D-5L utility scores at diagnosis and association with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR) (Oral presentation)

MRDR Annual Investigator and Interest Group Meeting (live webinar, 2021)

• Andrew Spencer, Real world myeloma in ANZ: registry progress and results
• P Joy Ho, Impact of biomarker (SLiM) inclusion to MM diagnostic criteria: diagnosis with SLiM alone versus end organ damage (CRAB) in the ANZ MRDR
• Khai Li Chai, Variation in use of Immunoglobulin in patients with myeloma
• Kate Vandyke, C-terminal telopeptide 1 (CTX-1) as a marker of high risk for progressing from smouldering to active myeloma 
• Naomi Aoki, Asia-Pacific MRDR: progress and results

Blood 2021, (virtual conference)

• PJ Ho, The impact of SLiM criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcome from the ANZ MRDR (Oral presentation)
• A Tedjaseputra, Tandem autologous-allogeneic-SCT in relapsed multiple myeloma: a joint report from the Alfred and Myeloma and Related Diseases Registry (MRDR) (poster)
• R Cao, Causes of death in multiple myeloma in Australia: results from the Australian and New Zealand Myeloma and Related Diseases Registry (Narrated poster)
• E Moore, Higher EQ-5D-5L utility scores at diagnosis are associated with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR) (Narrated poster)

International Myeloma Workshop, Sep 2021 (hybrid conference, Vienna-based)

• PJ Ho, The impact of SLiM criteria in myeloma in a real-life population: clinical characteristics, treatment and outcome from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR) (Narrated poster)
• A Tedjaseputra, Tandem autologous + non-myeloablative allogeneic stem cell transplantation in relapsed multiple myeloma: an Australian joint report from the Alfred and Myeloma and Related Diseases Registry (MRDR) (poster)

Nursing Symposium, IMW

• E Moore, Higher EQ-5D-5L utility scores at diagnosis are associated with improved overall survival in Australian patients with multiple myeloma: Results from the Australian & New Zealand (ANZ) Myeloma and Related Diseases Registry (MRDR) (Oral presentation)

Using PROMs ‘Down-under’ – Supported by ISOQOL, July 2021 (virtual Sydney-based conference)

• E Moore, Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomised controlled trial (short oral presentation)

Monash SPHPM Registry Meeting 2021

• A Irving, EpiMAP Myeloma (Oral presentation)

2020

ASH 2020 (virtual)

• J. Ho, The impact of SLiM criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcomes from the ANZ MRDR (narrated poster)
• K. Huynh, The Asia-Pacific MRDR: preliminary results of real-world treatment patterns and clinical outcome (abstract)

MRDR Annual Interest Group Meeting (held by webinar, during the 3^rd NMW, Australia 2020)

• A. Spencer, Myeloma in ANZ: MRDR progress and results
• C. Forsyth, Registry participation in a rural/regional setting
• D. Petrie, Epidemiological Modelling to deliver better care for Australians with MM
• K. Huynh, Asia Pacific MRDR: progress and results
• A. Spencer, AMARC: early phase clinical trials in multiple myeloma

3rd National Myeloma Workshop, Australia 2020 (virtual)

• A. Spencer, Early disease progression identifies an ultra-high risk sub-group of newly diagnosed multiple myeloma – A report from the MRDR
• J. Ho, The impact of SLiM criteria in myeloma in a real-life population: patient & disease characteristics, treatment and outcome from the ANZ MRDR (Poster)
• R. Cao, Infection is a major contributor to causes of death in multiple myeloma: results from the ANZ MRDR (Poster)
• N. Khajornjiraphan, Outcomes of bortezomib vs lenalidomide in patients with NDMM ineligible for ASCT – initial results from the ANZ MRDR (Poster)
• A. Jackson, Outcome of patients with multiple cytogenetic abnormalities at diagnosis: Results from the ANZ  MRDR (Poster)

Monash SPHPM Registry Meeting 2020

• E. Moore/K Huynh, The Myeloma and Related Diseases Registry (MRDR) and the Asia Pacific arm of the MRDR (APAC MRDR) - an overview (invited)

Haematology Society of Taiwan Meeting 2020

• H. Quach, The Australian experience of patients with RRMM (MRDR data used) (invited)

European Haematology Association Congress 2020 (virtual)

• K. Bergin, The myeloma landscape in Australia and New Zealand (ANZ): the first seven years of the Myeloma and Related Diseases Registry (MRDR) (Poster)

2019

A. Spencer, Real world outcomes for newly diagnosed patients with functional high-risk myeloma: a myeloma and related diseases registry analysis, ASH, Orlando, USA, December 2019

Blood 2019, October, Perth, Australia

• A. Spencer et al. MRDR Interest Group breakfast meeting
• J. Zhao et al., Real-world treatment patterns in relapsed/refractory multiple myeloma in Australia: results from the Myeloma and Related Diseases Registry.
• E. Moore et al., Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomised controlled trial.
• H. Blacklock et al., Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry.

International Myeloma Workshop 2019, September, Boston, USA

• H. Blacklock et al., Pacific Islanders with multiple myeloma are younger and have inferior survival when compared to other ethnicities: a study from the Australian and New Zealand Myeloma and Related Diseases Registry (MRDR, Poster)
• P. Mollee et al., Receiving four or less cycles of therapy predicts poor survival in newly diagnosed transplant ineligible patients with myeloma who are treated with bortezomib-based induction (Poster)
• E. Moore et al., Patient-reported outcome measures in multiple myeloma: real-time reporting to improve care (My-PROMPT) - a pilot randomised controlled trial

E. Moore et al., Health-related quality of life at diagnosis in multiple myeloma: EQ-5D-5L results from the MRDR and comparison with an Australian population norm (Poster), Alfred Week, June 2019

E. Moore et al., Data with impact, Myeloma UK Patient Registry Stakeholder Workshop. London, April 2019

2018

Inaugural Clinical Registries Summit, SPHPM, Monash, November 2018

• A. Spencer. The Myeloma and Related Diseases Registry
• N. Aoki, E. Moore. The APAC MRDR and other MRDR International Collaborations

Blood 2018, October, Brisbane

• A. Spencer et al., MRDR Interest Group breakfast meeting
• Z. McQuilten et al., Predictors of early mortality in multiple myeloma: Results from the ANZ MRDR
• K. Bergin et al., The MRDR: the first five years - the myeloma landscape in ANZ (Nominated for HSANZ Outstanding Young Investigator Award)
• E. Moore et al., Health-related quality of life at diagnosis in multiple myeloma: EQ-5D-5L results from the MRDR and comparison with an Australian population norm (Poster - Awarded Snowdome Foundation Haematology Nurse Myeloma Travel grant: $2500)

2nd National Myeloma Workshop, Yarra Valley, Australia, September 2018

• E. Moore et al., Health-related quality of life at diagnosis in multiple myeloma: EQ-5D-5L results from the Myeloma and Related Diseases Registry (Poster)
• Z. McQuilten et al., Predictors of early mortality in multiple myeloma: Results from the Australian and New Zealand Myeloma and Related Diseases Registry (Poster)

A. Spencer. Real world outcomes from the Myeloma and Related Diseases Registry. 3rd Annual Educational Seminar, Myeloma Special Practice Network, HSANZ Nurses Group, Royal Adelaide Hospital: August 2018

E. Moore. News from the Myeloma and Related Diseases Registry. Registry Special Interest Group meeting, SPHPM, Monash: July 2018

E. Moore and T. King, Growth and outcomes of the Myeloma and Related Diseases Registry. Quality of Life Office meeting, University of Sydney, July 2018

E. Moore et al., Maturing data from the Australia and New Zealand Myeloma and Related Diseases Registry (Poster), Alfred week, The Alfred Hospital, June 2018

K. Bergin et al., Utilisation Rates of Upfront Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma:  a report on behalf of the MRDR (Poster), EBMT, Lisbon, March 2018

2017

HAA 2017, November, Sydney

• A. Spencer et al., MRDR Interest Group meeting
• J. Ho, Renal impairment in myeloma: patient & disease characteristics, treatment, stem cell transplant & outcomes from the ANZ MRDR
• H. Blacklock, Polynesian ethnicity and outcomes for multiple myeloma in New Zealand: a single centre study from the ANZ MRDR (Poster)
• E. Moore et al., Patient reported outcome measures in multiple myeloma: real-time reporting to improve care (methodology of the My-PROMPT study) (Poster)

J. Ho, Renal impairment in myeloma: patient characteristics, treatment modalities, stem cell transplant & outcomes from the ANZ MRDR (Poster), European Haematology Association Congress, June 2017 

A. Spencer, The myeloma and related diseases registry: a tool for practice improvement, Victorian Integrated Cancer Services Conference, Melbourne, May 2017

A. Kalff, Myeloma Australia, Medical scientific advisory group (MSAG) meeting, Melbourne, May 2017

International Myeloma Workshop, New Delhi, February 2017

• K. Bergin et al., Rates of Upfront Autologous Stem Cell Transplantation in Newly Diagnosed Multiple Myeloma (Poster)
• E. Moore et al., Maturing data from the ANZ Myeloma and Related Diseases Registry (Poster)

Talks including reference to or introduction of the MRDR:

• H. Blacklock/T. King, National Haematology Nurses meeting, September 2017

2016

E. Wood, Australian Centre for Blood Diseases and Monash Health Research Symposium, Melbourne, November 2016 

HAA, Melbourne, November 2016

• A. Spencer et al., MRDR Interest Group meeting
• K. Bergin et al. Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma
• E. Moore et al. Renal impairment in myeloma: Characteristics and outcomes in patients with and without renal impairment in the ANZ Myeloma and Related Diseases Registry

National Myeloma Workshop, Yarra Valley, Vic, September 2016

• Z. McQuilten, Putting the pieces together – Epidemiology Practice and Outcomes in Australia and New Zealand,
• K. Bergin et al. Rates of Upfront Autologous Stem Cell Transplantation (ASCT) in Newly Diagnosed Multiple Myeloma (Poster)
• E. Moore et al. Renal impairment in myeloma: Characteristics and outcomes in patients with and without renal impairment in the ANZ Myeloma and Related Diseases Registry (Poster)

E. Moore, MRDR: Maturing data, HSANZ Nurses Group, Myeloma Special Practice Network Education Seminar, August 2016

E. Moore, MRDR: sustaining growth, Monash SPHPM Registry SIG, June 2016

A. Spencer, MRDR presentation to ALLG, ALLG Scientific Meeting, May 2016

B. Rosengarten, Myeloma Awareness Day Meeting, Sydney, May 2016

Talks including reference to or introduction of the MRDR:

• S. Gibbs, Myeloma lectures, Royal Darwin Hospital, Aug 2016

2015

E. Wood, Australian Centre for Blood Diseases and Monash Health Research Symposium, Melbourne, November 2015

A. Spencer, Korean Society of Hematology annual meeting, Seoul, November 2015

HAA, Adelaide October 2015

• E. Moore et al., Real world management of multiple myeloma: Initial results from the Australia and New Zealand Myeloma and Related Diseases Registry (Poster)
• A. Spencer, MRDR Interest Group meeting

E. Moore et al., Real world management of multiple myeloma: Initial results from the Australia and New Zealand Myeloma and Related Diseases Registry (Poster), International Myeloma Workshop, Rome, September 2015

Talks including reference to or introduction of the MRDR:

• A. Kalff, Binding site Educational Workshop, Melbourne, November, 2015
• A. Kalff, Myeloma Australia, Medical scientific advisory group (MSAG) meeting, Melbourne, November, 2015
• T. King, Update from IMW 2015 Rome: Nursing Symposium. HSANZ NG NSW Dinner Meeting. Sydney, November 2015 (Poster)
• T. King, Best practice in the administration of chemotherapy: Bortezomib focus. Tata Memorial Hspt Mumbai; Cancer Institute Chennai; Apollo Hospital Chennai; All India Institute of Medical Sciences (AIMS) Delhi; Rajiv Gandhi Cancer Institute Delhi India, August, 2015
• A. Kalff, Myeloma Australia, medical scientific advisory group (MSAG) meeting, Melbourne, May, 2015

2014

A. Spencer, Myeloma Scientific Advisory Group, Myeloma Foundation Australia, Melbourne, Victoria

A. Spencer, MRDR Interest Group Meeting, HAA, Perth, Western Australia, October 2014

Talks including reference to or introduction of the MRDR:

• T. King, The Clinical Care of Multiple Myeloma Patients with Targeted Therapy. Taipei, Taiwan, November 2014
• T. King, The Clinical Care of Multiple Myeloma Patients with Targeted Therapy. Kaohsiung, Taiwan, November 2014
• T. King, Making sense of myeloma: An overview of treatment. Leukaemia and Blood Cancer Foundation & HSANZ Nurses Group Educational meeting for nurses, September 2014 
• T. King, Myeloma: An overview of disease, treatments and management of side effects. Leukaemia and Blood Cancer Foundation Patient and Family Forum Auckland New Zealand, September 2014
• T. King, The Clinical Care of Multiple Myeloma Patients. The First Affiliated Hospital of College of Medicine Zhejiiang University. Hangzhou, China, February 2014
• T. King, The Clinical Care of Multiple Myeloma Patients. Shanghai Changzheng, Shanghaim, China, February 2014
• T. King, The Clinical Care of Multiple Myeloma Patients. Institute of Haematology and Blood Diseases Hospital Chinese Academy of Medical Sciences. Tianjin, China, February 2014

2013

A. Spencer HAA Investigator Meeting, Gold Coast, Queensland